ZA8.F ZYMEWORKS DL-00001

Healthcare Biotechnology Frankfurt Exchange
26.18 EUR
Close of Nov 12, 2026
15.40 27.80
Market cap
EUR 1.81B
P/E
55.8x
P/B
8.41x
ROE
43.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ZA8.F undervalued?

Graham number

The Graham number of ZYMEWORKS DL-00001 cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ZYMEWORKS DL-00001 fundamental analysis

No fundamental analysis for ZYMEWORKS DL-00001 yet.

ZYMEWORKS DL-00001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ZYMEWORKS DL-00001

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; an…

Full company profile